Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine in Pulmonary Arterial Hypertension
NCT03638908Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2013
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluoxetine in pulmonary arterial hypertension (PAH), sponsored by UT Southwestern Medical Center. Primary endpoint: Pulmonary Vascular Resistance at 24 weeks. Started Nov 2013; status: completed.
02
Drugs
fluoxetine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03638908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638908.